Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Matthew Halbower’s Pentwater Capital Doubled Its Stake in $HYC

Matthew Halbower’s Pentwater Capital purchased nearly 2.5 Million shares of Hypercom Corp (HYC) in May as the stock price plunged 20% since the end of April. At the end of March Pentwater had 1.95 Million shares of Hypercom when the stock price was nearly $12. Hypercom’s shares were below $4 in September 2010 and several insiders were buying at the time. Alex Meruelo, a large shareholder, bought more than 250 thousand shares at prices between $3.13 and $3.89. The same Alex Meruelo sold 2.8 Million shares of HYC at prices between $11.50 and $12.50. Usually insider sales aren’t very meaningful but not when the same insider reverses his opinion after a short period of time and a 200+% increase in the stock price.


The 20% decline in Hypercom’s stock was enough to make Matthew Halbower double his position. There are other hedge fund managers who are bullish about Hypercom as well. Cliff Asness’ AQR had $46 Million, Phill Gross’ Adage Capital had $31 Million, and Israel Englander’s Millenium Management had $15 Million in HYC at the end of March.

Matthew Halbower launched Pentwater Capital in 2007. He specializes in merger arbitrage and event-driven investing. Prior to starting Pentwater Halbower worked at Deephaven Capital following event-driven and distressed asset trading strategies.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!